Price
$9.76+155.50%Social Signal Score
Analyst Ratings
13 analystsRevenue
$10.64M+329.15%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Carl Hansen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 562
- Beta
- 1.19
- Country
- CA
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 4.50
Financials
Revenue
$10.64M+329.1%Net Income
$-40.76MEBITDA
$-36.01MFree Cash Flow
$25.30MEPS (diluted)
$-0.13Shares Outstanding (diluted)
318.05M+110.6%Operating Expenses
$57.15MCash & Debt
$764.42MReturn of Capital
$0.00Revenue by Segment (annual)
$75.13MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $75.13M | $-146.41M | $-0.49 |
| 2024 | $28.83M | $-162.86M | $-0.55 |
| 2023 | $38.02M | $-146.40M | $-0.51 |
| 2022 | $485.42M | $158.52M | $0.56 |
| 2021 | $375.20M | $153.46M | $0.56 |
| 2020 | $233.16M | $118.92M | $0.45 |
| 2019 | $11.61M | $-2.21M | $-0.01 |
| 2018 | $8.83M | $309.0K | $0.00 |
Valuation
ABCLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
40-20.00%Social Signal Score
Mentions (19)
- Newsmarketbeat.com·10h ago·Negative
AbCellera Biologics Targets 2027 Phase 3 Trial for Hot Flash Drug AbCellera Biologics NASDAQ: ABCL is targeting a phase 3 trial of its experimental hot flash treatment around the middle of 2027, as it prepares to release further phase 2 data and discuss the development path with regulators, CEO Carl Hansen said at the UBS Biopharma Conference in London.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
AbCellera Biologics Inc. (ABCL) Presents at UBS Global Biopharma Conference 2026 Transcript AbCellera Biologics Inc. (ABCL) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - Newsmarketbeat.com·6d ago·Neutral
AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot flash treatment ABCL635 into late-stage studies, with a registrational trial potentially starting around the middle of 2027, Chief Executive Carl Hansen said at the Jefferies 2026 Global Healthcare Conference in London.
View source ↗ - Newsseekingalpha.com·9d ago·Positive
AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript AbCellera Biologics Inc. ( ABCL ) Stifel 2026 Healthcare Conference 2026 November 10, 2026 7:00 PM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Stephen Willey Stifel, Nicolaus & Company, Incorporated, Research Division All right.
View source ↗ - Newsmarketbeat.com·10d ago·Negative
AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot-flash treatment ABCL635 into late-stage development next year after a midstage study produced stronger-than-expected efficacy results, CEO Carl Hansen said at a Stifel event.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·13d ago·Neutral
What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call AbCellera Biologics NASDAQ: ABCL plans to advance its experimental hot flash treatment ABCL635 into late-stage development in 2027 after reporting positive mid-stage results, while shelving further development of a separate antibody candidate for now.
View source ↗ - Newszacks.com·13d ago·Negative
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.19 per share a year ago.
View source ↗ - Newsbusinesswire.com·45d ago·Neutral
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.
View source ↗ - Newszacks.com·61d ago·Positive
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
View source ↗ - Newsbusinesswire.com·67d ago·Neutral
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
View source ↗ - Newsbenzinga.com·89d ago·Neutral
What'sGoing On With AbCellera Biologics Stock On Tuesday? AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.
View source ↗ - Newsseekingalpha.com·97d ago·Neutral
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
View source ↗ - Newsbusinesswire.com·101d ago·Neutral
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
View source ↗ - Newsbusinesswire.com·103d ago·Neutral
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
View source ↗ - Newsseekingalpha.com·104d ago·Positive
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
View source ↗ - Newsbenzinga.com·104d ago·Negative
AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark' AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/2 trial evaluating ABCL635.
View source ↗ - Newsmarketbeat.com·104d ago·Neutral
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associated with menopause.
View source ↗ - Newsbusinesswire.com·107d ago·Neutral
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Aug. 10, 2026.
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $-0.16 per share
Typical surprise +23.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-0.13 vs $-0.17beat
- Wed, Aug 5$-0.18 vs $-0.16miss
- Mon, May 11$-0.14 vs $-0.22beat
- Tue, Feb 24$-0.03 vs $-0.18beat
- Thu, Nov 6$-0.19 vs $-0.17miss
- Thu, Aug 7$-0.12 vs $-0.17beat
Estimates and results for ABCL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ABCL officers and directors.
- Bought
- $10.9m
- Sold
- —
27 trades
0 trades
- Booth Andrewbought
- Thermopylae Holdings Ltd.bought
- Hayden Michael Rbought
- Montalbano John S.bought
- Booth Andrewbought
- Hayden Michael Rbought
- Montalbano John S.bought
- Thermopylae Holdings Ltd.bought
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ABCL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
